tradingkey.logo

Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis

ReutersMay 22, 2025 11:08 AM

- Ascletis Pharma Inc 1672.HK:

  • ASCLETIS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ITS ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50, FOR THE TREATMENT OF PSORIASIS

  • ASCLETIS PHARMA INC - PHASE I TRIAL DOSING EXPECTED TO START IN Q3 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI